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23andMe, the Food and Drug Administration,
and the Future of Genetic Testing
OnNovember 22, 2013, the US Food and Drug Admin-
istration (FDA) effectively halted health-related direct-
to-consumer genetic testing in the United States by
sending a warning letter to 23andMe, the leading com-
pany in the field, directing it to stop providing such
testing.1 The FDA acted as the era of widespread, clini-
cal use of DNA sequencing rapidly approaches. The
agency’s action will contribute to changes in which
genetic tests are offered to patients and how testing is
provided.
Since 2007, Mountain View, California–based
23andMehasoffered—directly toconsumers,via itsweb-
site—a “Saliva Collection Kit and Personal Genome Ser-
vice.” The service identifies single nucleotide polymor-
phisms,orSNPs,variationsof individualbasepairswithin
the genome, using a microarray, often referred to as a
SNP chip. Based on its analysis of SNPs, 23andMe pro-
vided consumers with health-related information con-
cerning 254diseases and conditions aswell as informa-
tion on genealogy (such as percentage of Neanderthal
ancestry) and nondisease traits (dry- vs wet-type ear
wax, for example). However, SNPs rarely affect health
directly. Instead, SNP-based health information typi-
cally is based on statistical correlations between SNPs
and phenotypic traits that are found in whole-genome
association studies.
The FDA regulates genetic testing products as de-
vices when they are “intended for use in the diagno-
sis…or prevention of disease.”2 Although the FDA has
longconsideredhealth-relatedgenetic tests tobewithin
its jurisdiction, it has not regulated many of them. The
agency has chosen not to regulate genetic tests devel-
oped by a laboratory for its own use that are not a pre-
manufactured “kit,” perhaps because those tests are
regulated in part by the Clinical Laboratories Improve-
ments Amendments Act and are the subject of guide-
lines from the College of American Pathologists.
The FDA’s primary concernwithmedical devices is
whether they are safe and effective for their intended
use.Forgenetic tests,effectivenessencompasses2con-
cepts: analytic validity, howwell the testmeasureswhat
it purports to measure; and clinical validity, the accu-
racy of the results with regard to the presence or ab-
sence of a disease or condition. Using 23andMe’s kit as
anexample,analyticvalidity iscorrectly identifyingSNPs,
andclinicalvalidity isaccurately reportinganyhealthcon-
sequences. Notably, 23andMe provided this informa-
tiondirectly toconsumers.Consumerscouldseekaphy-
sician’sorageneticcounselor’sadviceaboutthemeaning
of the results but were not obliged to.
TheFDAordered23andMetostopmarketing itsper-
sonal genome service because it is an unapproved and
uncleareddevice. The company’swebsite had called its
personal genome service “the first step in prevention”1
of diseases such as diabetes and cancer, which clearly
sounds like something “intended for use in the diagno-
sis . . . or prevention of disease,”2 the statutory defini-
tion of a device.
The warning letter further explained that
23andMe must obtain the agency’s authorization for
each of the test’s 254 health-related uses, in essence,
requiring that 23andMe show that each use is both
analytically and clinically valid. Although 23andMe’s
service is generally thought to be analytically accurate,
it may nonetheless be impossible for the company to
meet both standards because the medical meaning of
SNPs is often uncertain. In 2009 and 2010, 3 groups
assessed the clinical validity of SNP testing results by
sending identical samples to different companies that
marketed genetic tests directly to consumers.3-5 The
risk assessments differed markedly. In one study,3
about a third of the time, one company identified the
SNPs of a customer as indicating a high risk for disease;
another company identified the same polymorphisms
as low risk.3
The FDA also expressed concern about delivering
health-related results directly to consumers. Even if the
clinical interpretation were correct, consumers might
draw the wrong medical conclusion from the results
withoutprofessional guidance. Theymightoverreact to
bad news through inappropriate interventions, such as
changing thedoseof amedication, oroverreact togood
news by, for example, avoiding still-useful medical in-
terventions, such as mammograms, after receiving ge-
netic information about their breast cancer risk.
After a vague initial response,6 23andMe an-
nounced that it would stop providing health informa-
tion to new customers.7 The company, however, con-
tinues to market its personal genome service, but only
provides “ancestry-related genetic information and . . .
raw data without 23andMe’s interpretation.”7 Al-
though23andMecouldeventually challenge theFDA in
court, such a challenge would probably not succeed. It
is more likely that 23andMewould work to provide the
FDA with evidence that its tests are safe and accurate,
although it is not clearwhat evidence theagencywould
require.
If 23andMe is unable to satisfy the FDA that its test
is safeandeffective, thewarning lettermaymarktheend
of direct-to-consumer genetic testing in the United
States. In 2012, 23andMe’smain competitors,Navigen-
ics and deCODEme, were sold to other firms, which
quicklystoppedofferingdirect-to-consumertests.Some
smaller firmscontinuetooffer suchtests, although in the
aftermath of the FDA’s warning to 23andMe, they, too,
may stop.
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Genetic testing delivered throughmedical professionals, how-
ever,will continueandgrow.TheFDAwarned23andMebecause its
tests were sold as kits. Had a doctor ordered genetic tests from a
clinical laboratory that used tests it had developed, the agency, un-
der its current policy, would not have intervened, even if the re-
sults had questionable clinical validity.
Eventhiskindofgenetic testingwill change, thankstobothtech-
nologyandregulation.Sequencingof thewholegenomeandexome,
the portion of the genome that codes information for protein syn-
thesis, is rapidly overtaking SNP chip or single-gene tests. The hu-
mangenomecannowbesequenced inabout24hours.Over the last
decade, the cost of whole-genome sequencing with high-
throughput (next-generation) genomic sequencers has fallen from
roughly $500 million to less than $5000. The move to this next-
generation sequencing is already happening, both in industry and
at FDA. On November 19, 2013, 3 days before sending the warning
letter to 23andMe, the FDA authorized Illumina, a biotechnology
company based in San Diego, California, to market 4 next-
generation sequencingproducts: a sequencingplatform, 2 tests for
cystic fibrosis that use the platform, and a “universal kit” that al-
lows laboratories to use the platform and develop their own tests
for any genetic variation.8
TheFDA’s authorizationof a high-throughput sequencingplat-
form, cystic fibrosis tests, and universal kit was presumably based
on a favorable assessment of their analytic validity. But the autho-
rization for a universal kit was not accompanied by a requirement
that the clinical validity of the testing be demonstrated. Thus, pa-
tients couldbe told that theyhaveparticulargeneticvariationswith-
out any regulation of the explanations from laboratories of what
those variations mean.
The FDA has said, without disclosing details, that it is inter-
ested in a risk-based approach to regulating genetic tests that are
developed by laboratories. Stronger regulation would be applied
to tests that are deemed riskier. The continued delay in announc-
ing a proposed policy might reflect the inherent difficulty of deter-
mining clinical validity for genetic tests. For example, although the
clinical validity of some gene variations is well known—2 copies of
the ΔF508-CFTR1 allele lead to cystic fibrosis, and the 185delAG
deletion in BRCA1 exposes women to a significantly higher risk of
breast cancer—many stretches of DNA have either only weak evi-
dence for their health effects or are simply variants of unknown
significance.
TheFDA’swarning letter to23andMemarks theendof theagen-
cy’s willingness to allow unverified health claims for direct-to-
consumer genetic tests. Whether it marks the end of direct-to-
consumer genetic testing depends on the FDA’s standards for their
clinical validity. The agency’s nearly simultaneous authorization of
the firstnext-generationgenetic sequencingproductsmarks thebe-
ginningof large-scalewhole-genomeandexomesequencingforclini-
cal use. But the application of these technologies also depends on
the standards for clinical validity. Requiring proof of clinical validity
for eachvariantwouldhaltmost, if not all, genetic testing. But if the
FDA does not require any evidence of clinical validity, it would in-
vite chaos—andquacks.Wemayhave reached theendof one regu-
latory and technological era for genetic testing, but another is just
beginning.
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